Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P01344
UPID:
IGF2_HUMAN
Alternative names:
Somatomedin-A; T3M-11-derived growth factor
Alternative UPACC:
P01344; B3KX48; B7WP08; C9JAF2; E3UN45; P78449; Q14299; Q1WM26; Q9UC68; Q9UC69
Background:
Insulin-like growth factor II (IGF2), also known as Somatomedin-A, plays a pivotal role in growth and development. It is a major fetal growth hormone in mammals, crucial for fetoplacental development and involved in tissue differentiation. In adults, IGF2 is key in glucose metabolism across various tissues. It acts as a ligand for integrin, essential for IGF2 signaling, and supports muscle differentiation by regulating MYOD1 function.
Therapeutic significance:
IGF2's involvement in Silver-Russell syndrome, characterized by growth retardation and craniofacial features, highlights its therapeutic potential. Understanding IGF2's role could open doors to novel strategies for managing growth-related disorders.